Pirfenidone Prevents the Development of a Vulnerable Substrate for Atrial Fibrillation in a Canine Model of Heart Failure | Zendy

Ken W. Lee | Zendy; Thomas H. Everett | Zendy; Dulkon Rahmutula | Zendy; María José Guerra Palmero | Zendy; Emily Wilson | Zendy; Chunhua Ding | Zendy; Jeffrey E. Olgin | Zendy

Open Access

Pirfenidone Prevents the Development of a Vulnerable Substrate for Atrial Fibrillation in a Canine Model of Heart Failure

Author(s) -

Ken W. Lee,

Thomas H. Everett,

Dulkon Rahmutula,

María José Guerra Palmero,

Emily Wilson,

Chunhua Ding,

Jeffrey E. Olgin

Publication year - 2006

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.106.624320

Subject(s) - medicine , atrial fibrillation , cardiology , heart failure , pirfenidone , fibrosis , interquartile range , heart disease , idiopathic pulmonary fibrosis , lung

Atrial fibrosis is an important substrate in atrial fibrillation (AF), particularly in the setting of structural heart disease. In a canine model, congestive heart failure (CHF) produces significant atrial fibrosis and the substrate for sustained AF. This atrial remodeling is a potential therapeutic target. The objective of the present study is to evaluate the effects of the antifibrotic drug pirfenidone (PFD) on arrhythmogenic atrial remodeling in a canine CHF model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research